TR200000272T2 - Antitümör ve antimetastaz maddeleri olarak o-ikameli hidrosikumaranon türevleri. - Google Patents

Antitümör ve antimetastaz maddeleri olarak o-ikameli hidrosikumaranon türevleri.

Info

Publication number
TR200000272T2
TR200000272T2 TR2000/00272T TR200000272T TR200000272T2 TR 200000272 T2 TR200000272 T2 TR 200000272T2 TR 2000/00272 T TR2000/00272 T TR 2000/00272T TR 200000272 T TR200000272 T TR 200000272T TR 200000272 T2 TR200000272 T2 TR 200000272T2
Authority
TR
Turkey
Prior art keywords
antitumor
hydrocycumaranone
derivatives
substituted
antimetastatic agents
Prior art date
Application number
TR2000/00272T
Other languages
English (en)
Inventor
De Cillis Gianpiero
Di Domenico Roberto
Koenig Bernhard
Oliva Ambrogio
Original Assignee
F. Hoffmann -La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann -La Roche Ag filed Critical F. Hoffmann -La Roche Ag
Publication of TR200000272T2 publication Critical patent/TR200000272T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Formül (I) bilesikleri, uPA (ürokinaz türü plazminojen katalizörü) antagonist aktivitesine sahiptir ve antitümör ve/veya antimetastaz maddeleri olarak kullanilabilmektedir. Burada R,R',A,B,T ve x tarifnamede tanimlandigi gibidir.
TR2000/00272T 1997-07-31 1998-07-23 Antitümör ve antimetastaz maddeleri olarak o-ikameli hidrosikumaranon türevleri. TR200000272T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP98106946 1998-04-16

Publications (1)

Publication Number Publication Date
TR200000272T2 true TR200000272T2 (tr) 2000-09-21

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00272T TR200000272T2 (tr) 1997-07-31 1998-07-23 Antitümör ve antimetastaz maddeleri olarak o-ikameli hidrosikumaranon türevleri.

Country Status (21)

Country Link
US (1) US6200989B1 (tr)
EP (1) EP1012147B1 (tr)
JP (1) JP3241711B2 (tr)
KR (1) KR100343067B1 (tr)
AR (1) AR013374A1 (tr)
AT (1) ATE308535T1 (tr)
AU (1) AU745839B2 (tr)
BR (1) BR9811589A (tr)
CA (1) CA2296476A1 (tr)
DE (1) DE69832184D1 (tr)
HR (1) HRP20000031A2 (tr)
HU (1) HUP0004221A2 (tr)
ID (1) ID24525A (tr)
IL (1) IL134193A0 (tr)
MA (1) MA26528A1 (tr)
NO (1) NO20000366D0 (tr)
PE (1) PE106099A1 (tr)
PL (1) PL338614A1 (tr)
TR (1) TR200000272T2 (tr)
UY (1) UY25114A1 (tr)
WO (1) WO1999006387A2 (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736869B2 (en) * 1999-01-30 2001-08-02 Roche Diagnostics Gmbh O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
US7514406B2 (en) * 2001-11-27 2009-04-07 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
WO2003051347A1 (en) * 2001-12-19 2003-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2004076444A2 (en) * 2003-02-25 2004-09-10 F. Hoffmann-La Roche Ag Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
WO2008050857A1 (en) * 2006-10-27 2008-05-02 The University Of Tokyo Amide compound or salt thereof, and biofilm formation inhibitor, biofilm remover and bactericide each using the amide compound or salt thereof
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
CN111542523B (zh) 2017-11-24 2024-03-29 朱比连特埃皮斯科瑞有限责任公司 作为prmt5抑制剂的杂环化合物
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
BR112020023115A2 (pt) * 2018-06-05 2021-02-02 Praxis Biotech LLC inibidores da via integrada de resposta a tensão
EP3982965A4 (en) 2019-06-12 2023-01-25 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (de) 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3209271A1 (de) 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
JPH0655152B2 (ja) * 1984-08-13 1994-07-27 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド ミナクチビンの製造方法
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
EP1012147A2 (en) 2000-06-28
ATE308535T1 (de) 2005-11-15
PL338614A1 (en) 2000-11-06
WO1999006387A2 (en) 1999-02-11
AU9155998A (en) 1999-02-22
US6200989B1 (en) 2001-03-13
NO20000366L (no) 2000-01-25
HUP0004221A2 (hu) 2001-04-28
KR20010022362A (ko) 2001-03-15
NO20000366D0 (no) 2000-01-25
EP1012147B1 (en) 2005-11-02
PE106099A1 (es) 1999-11-11
KR100343067B1 (ko) 2002-07-03
MA26528A1 (fr) 2004-12-20
UY25114A1 (es) 2001-01-31
AR013374A1 (es) 2000-12-27
JP3241711B2 (ja) 2001-12-25
CA2296476A1 (en) 1999-02-11
DE69832184D1 (de) 2005-12-08
IL134193A0 (en) 2001-04-30
WO1999006387A3 (en) 1999-04-22
AU745839B2 (en) 2002-04-11
BR9811589A (pt) 2000-09-19
JP2001512113A (ja) 2001-08-21
ID24525A (id) 2000-07-20
HRP20000031A2 (en) 2000-10-31

Similar Documents

Publication Publication Date Title
TR200000272T2 (tr) Antitümör ve antimetastaz maddeleri olarak o-ikameli hidrosikumaranon türevleri.
ES2175066T3 (es) Antagonistas triciclicos de la vasopresina.
DE69012888D1 (de) Plasminogenaktivator.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69925133D1 (de) Pyrrolobenzodiazepine
DE69610627D1 (de) Neuartige peptidderivate
DE59709414D1 (de) Oxyiminopregnancarbolactone
FI955720A0 (fi) Urokinaasireseptoriaktiivisuuden peptidi-inhibiittoreita
ATE126215T1 (de) Anti-entzündende 4-aminophenol-derivate.
NO982987D0 (no) Amidinoproteasehemmere
ZA949151B (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents.
NO981393D0 (no) Guanidinoproteasehemmere
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
GB2324091A (en) Metalloproteinase inhibitors
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.
ATE28188T1 (de) Antikonvulsive mittel.
DE68914522T2 (de) Isobenzothiazolon als chromogenische Thiol-Indikatoren und dessen Derivate.
TR199701298T1 (tr) Tetralinler.
ATE100094T1 (de) Imidazolantiarrythmische mittel.
BG105252A (en) Isoquinolines as urokinase inhibitors
AU4511299A (en) Imidazotriazolopyrimidines used as a drug having an adenosine antagonist activity
DE60003560D1 (de) 1,2-dihydro-1-oxo-pyrazino[1,2-]indolederivate
FI950101A (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
ATE222255T1 (de) 14-substituierte marcfortine und derivate als antiparasitäre mittel
RU96112258A (ru) Способ усиления солнцезащитной активности фотозащитных агентов